证券代码：688329 证券简称：艾隆科技 公告编号：2025-036 苏州艾隆科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为积极响应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动 的倡议》，深入贯彻党的二十大和中央金融工作会议精神，落实国务院《关于进 一步提高上市公司质量的意见》要求，推动公司高质量发展和投资价值提升，保 护投资者尤其是中小投资者合法权益，助力资本市场健康发展，苏州艾隆科技股 份有限公司（以下简称"公司"）于 2025 年 5 月 21 日披露了 2025 年度"提质增效 重回报"专项行动方案。2025 年上半年，公司根据行动方案内容，积极开展和落 实各项工作，现将 2025 年上半年主要进展及成效情况报告如下： 一、聚焦主营业务，提升经营质量 但实现归属于母公司所有者的净利润-839.02 万元，较上年同期上升 55.47%。与 此同时，公司进一步落实预算管理工作，做好成本优化和费用管控，2025 年上 半年，公司主营业务成本 6,656.78 万元，同比下降 5.68 ...

| 证券简称：艾隆科技 公告编号：2025-038 | 证券代码：688329 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 苏州艾隆科技股份有限公司 | | | | | | | | 年半年度计提及转回资产减值准备的公告 | 2025 关于 | | | | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | | 一、本次计提减值准备情况概述 | | | | | | | | 根据《企业会计准则》以及公司会计政策、会计估计的相关规定，为了真实、 | | | | | | | | 2025 6 30 年 月 日的财务状况，本着谨慎性原则，对截至 | 准确地反映公司截至 | | | | | | | 值 准 备 。 2025 年 半 年 度 公 司 转 各 类 信 用 及 产 减 值 准 | 应 的 减 | 回 | 资 | 备 | 共 | 计 | | 单位：元 | | | | | | | | 202 ...

Company Overview - Suzhou Ailong Technology Co., Ltd. focuses on intelligent management of medical supplies, providing comprehensive solutions for healthcare institutions globally [4][10] - The company has established a complete product line covering smart pharmacies, smart wards, smart warehousing, and pharmaceutical information systems [4][10] - As of the reporting period, Ailong's products have been implemented in over 1,200 healthcare institutions, including more than 580 top-tier hospitals in China [4] Financial Performance - For the first half of 2025, the company reported a net profit attributable to shareholders of -8.39 million yuan, a year-on-year improvement of 55.47% [1][2] - Total revenue for the same period was approximately 131.08 million yuan, reflecting an 8.11% decrease compared to the previous year [2] - The total profit for the period was -7.55 million yuan, showing a significant improvement of 62.56% from -20.16 million yuan in the same period last year [2][3] Business Model - The company employs a mixed sales model combining direct sales and distribution through agents [8] - Direct sales target pharmaceutical supply chain service companies, healthcare institutions, and government entities, primarily through tendering processes [8] - The OEM procurement model allows the company to focus on core technology development while outsourcing some production to partners [7][8] Industry Context - The medical supply intelligent management system industry in China has evolved from initial automation attempts in the 1990s to comprehensive, integrated solutions in recent years [10] - Regulatory changes and the increasing complexity of healthcare demands have driven the shift towards "whole-hospital, integrated" solutions [10] - The industry is characterized by a growing need for automation and information integration to enhance efficiency and safety in medical supply management [10] Product Development - Ailong Technology emphasizes continuous innovation and product development, integrating automation and information technology to enhance operational efficiency [4][5] - The company has developed various products, including intelligent dispensing systems, automated drug storage, and management software for narcotic drugs [5][6] - Recent innovations include the "Ailong AI Assistant," which leverages AI to optimize various aspects of pharmaceutical management [7]

Core Insights - Suzhou Iron Technology Co., Ltd. reported a net profit attributable to shareholders of -8.39 million yuan for the first half of 2025, representing a year-on-year increase of 55.47%, but still resulting in a loss due to ongoing market conditions [1][2]. Company Overview - The total assets of the company at the end of the reporting period were approximately 1.36 billion yuan, a decrease of 1.69% compared to the end of the previous year [1]. - The company's revenue for the reporting period was approximately 131.08 million yuan, down 8.11% from 142.64 million yuan in the same period last year [1]. - The total profit for the period was -7.55 million yuan, showing an improvement of 62.56% compared to -20.16 million yuan in the previous year [1]. - The net profit attributable to shareholders was -8.39 million yuan, compared to -18.84 million yuan in the same period last year, marking a 55.47% improvement [1]. - The net profit after deducting non-recurring gains and losses was -18.09 million yuan, a decrease of 21.62% from -23.08 million yuan in the previous year [1]. Shareholder Information - The total number of shareholders at the end of the reporting period was 4,218 [2]. - The largest shareholder, Zhang Yinhua, holds 29.86% of the shares, followed by Xu Li with 10.96% [2][3].

苏州艾隆科技股份有限公司（以下简称"公司"）第五届监事会第七次会 议于 2025 年 8 月 11 日在公司会议室以现场方式召开，会议通知和补充通知已 分别于 2025 年 8 月 7 日和 8 月 10 日通过邮件的方式送达各位监事。本次会议 由监事会主席张春兰主持，会议应出席监事 3 名，实际出席 3 名。会议召开符 合《公司法》等法律法规以及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 证券代码：688329 证券简称：艾隆科技 公告编号：2025-039 苏州艾隆科技股份有限公司 第五届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 （二）审议通过《关于控股孙公司购买资产暨关联交易的议案》 监事会认为：公司控股孙公司医谷研究院本次关联交易是出于满足其发展 需要而进行的，同时符合公司整体发展战略，有利于公司及下属子公司的长期 可持续发展。同时，本次关联交易定价公允，不存在损害公司和全体股东尤其 是中小股东的 ...

Group 1 - The core viewpoint of the news is that Ailong Technology has significantly narrowed its losses in the first half of 2025, with a net profit attributable to the parent company of -8.39 million yuan, and it aims for a full-year profit target of 19.2 million to 29 million yuan [1] - The company anticipates that revenue will gradually be recognized as projects enter the acceptance phase in the second half of the year, combined with ongoing cost-saving measures, leading to an acceleration in performance improvement [1] Group 2 - Policy changes are a significant driver for Ailong Technology's business development, particularly the implementation of drug traceability codes in the medical insurance sector starting July 1, 2025, which presents substantial opportunities in the drug traceability field [2] - Ailong Technology has developed a leading "4π full-dimensional spherical scanning system" that has been well-received by users, enabling precise identification and collection of drug traceability codes without dead angles [2] Group 3 - The company has established a comprehensive product layout in the field of smart management of medical supplies, covering four core areas: smart pharmacies, smart wards, smart warehousing, and pharmaceutical information [3] - Ailong Technology's products are currently used in over 1,200 medical institutions in China, including more than 580 top-tier hospitals, maintaining a leading market share [3] Group 4 - Ailong Technology is accelerating its global expansion as part of its dual-driven strategy of "panoramic strategy and globalization," focusing on Southeast Asia as a key overseas market [4] - The company emphasizes its strong customization capabilities to provide tailored solutions for hospitals, leveraging its experience from the domestic market [4] Group 5 - The company has integrated AI technology into pharmaceutical management, transitioning traditional models to a "data-driven" approach, injecting new momentum into hospital pharmaceutical services [5] Group 6 - Looking ahead, Ailong Technology plans to focus on the development of its core business, continuously improve its business segments, and implement its "panoramic and global" development strategy [6] - The company aims to adjust its product brand strategies based on market demand changes and enhance cost optimization and expense control through refined management [6]

Core Viewpoint - Ailong Technology (688329.SH) reported a revenue of 131 million yuan for the first half of 2025, representing a year-on-year decrease of 8.11% [1] Financial Performance - The net profit attributable to shareholders was a loss of 8.39 million yuan [1] - The non-recurring net profit showed a loss of 18.09 million yuan [1] - Basic earnings per share were -0.11 yuan [1] Reasons for Performance Changes - The performance changes were primarily due to strengthened accounts receivable recovery, reversal of bad debt provisions, and an increase in government subsidies recognized in the current period compared to the same period last year [1]

格隆汇8月11日丨艾隆科技(688329.SH)公布，公司控股孙公司医谷研究院基于业务发展需要，拟向滁州 筑医台购买其开发建设的位于安徽省滁州市泉州路300号的1号厂房，为医谷研究院用于办公以及生产配 套等用途。本次交易对价预计为人民币1,350万元，资金来源为医谷研究院自有或自筹资金。截止本公 告披露日，公司尚未签署相关协议。 ...

格隆汇8月11日丨艾隆科技(688329.SH)公布半年度报告，报告期内，公司实现营业总收入13,107.68万 元，同比下降8.11%；实现归属于母公司所有者的净利润-839.02万元，同比增加55.47%；公司营业总成 本16,296.75万元，同比下降3.84%，其中主营业务成本6,656.78万元，同比下降5.68%；销售费用 2,778.87万元，同比下降20.46%，管理费用2,879.59万元，同比增加11.50%。 ...

艾隆科技（SH 688329，收盘价：22.88元）8月11日晚间发布半年度业绩报告称，2025年上半年营业收 入约1.31亿元，同比减少8.11%；归属于上市公司股东的净利润亏损约839万元；基本每股收益亏损0.11 元。2024年同期营业收入约1.43亿元；归属于上市公司股东的净利润亏损约1884万元；基本每股收益亏 损0.25元。 （文章来源：每日经济新闻） ...